ARCHIVES

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

This article is from The Cancer Letter archive.

Vol. 36 No. 1 | January 25, 2013

Download PDF Visit The Full Archive

Related Articles

NCCS Networker Volume 3 Issue 2, Spring 1989

April 13, 1989

NCI Announces New CREG Offer For In Vitro Chemical Carcinogenesis Tests

November 21, 1975

ASH Highlights: Improved Treatments For NHL, Poor Prognostic Factors For B-Cell In Children

January 30, 2004

Time Spent Sitting Associated With Total Mortality, Study Finds

July 30, 2010

NCI Goofs On Contract Notice, Won’t Change Improper Deadline

April 15, 1977

New ACS Structure Proposed, approved

August 6, 1993